Effect of denosumab versus zoledronic acid in patients with castrate-resistant prostate cancer and bone metastases: Subgroup analyses by prior SRE and baseline pain

Authors :: J. P. Maroto
Karim Fizazi
Joseph L. Chin
N.D. Shore
Kurt Miller
Ronaldo Damião
Amy Feng
Mindaugas Jievaltas
Yi Qian
C. Goessl
Matthew R. Smith
Karen Chung
Source :: Journal of Clinical Oncology. 29:4533-4533
Publication Year :: 2011
Publisher :: American Society of Clinical Oncology (ASCO), 2011.
Abstract: 4533 Background: Bone metastases from castrate-resistant prostate cancer (CRPC) are associated with osteoclast-mediated bone destruction and skeletal-related events (SREs). Denosumab is a fully hum...

Subjects :: Oncology
Cancer Research
medicine.medical_specialty
business.industry
Castrate-resistant prostate cancer
urologic and male genital diseases
medicine.disease
Surgery
Prostate cancer
Zoledronic acid
Denosumab
Internal medicine
Hum
Medicine
In patient
business
medicine.drug

Full Text Access

Tools